{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-002728","form_type":"8-K","ticker":"CVRX","cik":"0001235912","company_name":"CVRx, Inc.","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.671653+00:00","generated_at":"2026-05-16T10:47:22.811747+00:00","sec_items":["1.01","2.02","2.03","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CVRx amends debt facility to $100M, draws $10M; Q4 rev ~$16M (+4-5% YoY)","bullets":["Debt facility increased by $50M to $100M; $10M drawn at closing, total outstanding $60M; maturity extended to May 2031.","Q4 2025 preliminary revenue $15.9-16.1M (+4-5% YoY); full-year 2025 revenue $56.5-56.7M (+10-11% YoY).","FY2026 guidance: revenue $63-67M (+11-18% YoY); gross margin 84-86%; operating expenses $103-107M.","BENEFIT-HF trial: FDA IDE granted Nov 2025; applied for CMS coverage; net trial costs $20-30M over 5-7 years.","Cash and equivalents $75.7M as of Dec 31, 2025; 252 active implanting centers; 53 sales territories."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-002728","json":"https://secwatch.observer/filing/0001104659-26-002728.json","markdown":"https://secwatch.observer/filing/0001104659-26-002728.md","text":"https://secwatch.observer/filing/0001104659-26-002728.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1235912/000110465926002728/0001104659-26-002728-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1235912/000110465926002728/tm262733d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:47:22.811747+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1a9ce000683493ee8559e445d143f275bc07f69e","claim":"CVRx, Inc. incurred term loan of $10 million with Innovatus Life Sciences Fund I, LP at prime rate plus 2.65% maturing May 9, 2031.","evidence_excerpt":"revenue exceeds $100 million. The term loans continue to be secured by substantially all of the Company’s assets. Also on the Closing Date, the Company borrowed an additional $10 million under the Loan Agreement, bringing the total outstanding principal amount of term loans to $60 million. The Company has the option to draw (i) $15 million between June 1, 2027","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1235912/000110465926002728/0001104659-26-002728-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"term loan"},{"label":"Principal","value":"$10 million"},{"label":"Counterparty","value":"Innovatus Life Sciences Fund I, LP"},{"label":"Rate","value":"prime rate plus 2.65%"},{"label":"Maturity","value":"May 9, 2031"},{"label":"Event","value":"incurrence"}]},{"claim_id":"98217eb60a4c05c6bd2f46191c58c9a1f67c47a9","claim":"CVRx, Inc. amended credit facility of $50 million with Innovatus Life Sciences Fund I, LP at floating rate per annum equal to the sum of (i) the greater of (A) the prime rat maturing May 9, 2031.","evidence_excerpt":"Pursuant to the Amendment, (a) the terms loans available to the Company are increased by $50 million, to an aggregate principal amount of up to $100 million","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1235912/000110465926002728/0001104659-26-002728-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"credit facility"},{"label":"Principal","value":"$50 million"},{"label":"Counterparty","value":"Innovatus Life Sciences Fund I, LP"},{"label":"Rate","value":"floating rate per annum equal to the sum of (i) the greater of (A) the prime rat"},{"label":"Maturity","value":"May 9, 2031"},{"label":"Event","value":"amendment"}]},{"claim_id":"46af42d4631acb8ed1435c2f2469e3c2399e2be5","claim":"CVRx, Inc. amended Amendment with Innovatus Life Sciences Fund I, LP valued at $50 million (effective 2026-01-09).","evidence_excerpt":"On January 9, 2026 (the “Closing Date”), CVRx, Inc. (the “Company”) entered into an amendment (the “Amendment”) to its existing Loan and Security Agreement dated October 31, 2022, as previously amended on March 13, 2023 (as amended, the “Loan Agreement”), among the Company, Innovatus Life Sciences Fund I, LP, as the collateral agent and a lender, and the other lenders from time to time party thereto.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1235912/000110465926002728/0001104659-26-002728-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Innovatus Life Sciences Fund I, LP"},{"label":"Value","value":"$50 million"},{"label":"Effective","value":"2026-01-09"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}